How to appeal a Cigna c. difficile infection denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna c. difficile infection denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for c. difficile infection
Cited policy: Cigna Coverage Position on Rebyota (Fecal Microbiota, live-jslm)
Adult ≥18 yr. ≥1 CDI recurrence (i.e., 2nd CDI episode or later). Completion of standard-of-care antibacterial therapy for current CDI episode. Single 150 mL rectal administration 24-72 hours after final antibiotic dose. Not for treatment of active CDI.
How Cigna denies c. difficile infection — and how to counter it
Where Cigna pushes back: 1) Experimental / investigational; 2) Reserved for ≥3 recurrences; 3) Try traditional FMT first (cheaper); 4) Insufficient evidence base.
Counter-arguments that hold up: Rebyota was FDA-APPROVED on November 30, 2022 — the FIRST FDA-approved fecal microbiota product. Indication (per FDA label): prevention of recurrence of CDI in individuals ≥18 yr following antibiotic treatment for recurrent CDI (i.e., ≥1 prior recurrence — 2nd episode onward, NOT 3+). Approval based on PUNCH CD3 (Khanna Drugs 2022;82(15):1527-1538) — Phase 3 RCT, n=262, treatment success 70.6% Rebyota vs 57.5% placebo at 8 wk (Bayesian posterior probability of superiority 99.1%). Endorsed by ACG 2021 + AGA Living Guideline 2024 update. Traditional FMT remains investigational under FDA enforcement discretion; Rebyota is the regulatorily approved alternative.
What Cigna typically denies for c. difficile infection
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For c. difficile infection, expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the c. difficile infection treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Fidaxomicin (Dificid)
- Fidaxomicin extended-pulsed
- Vancomycin PO
- Vancomycin enema
- Bezlotoxumab (Zinplava)
- Rebyota
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna c. difficile infection denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for c. difficile infection?
For c. difficile infection, Cigna most often denies on: 1) Experimental / investigational; 2) Reserved for ≥3 recurrences; 3) Try traditional FMT first (cheaper); 4) Insufficient evidence base. The strongest counters: Rebyota was FDA-APPROVED on November 30, 2022 — the FIRST FDA-approved fecal microbiota product. Indication (per FDA label): prevention of recurrence of CDI in individuals ≥18 yr following antibiotic treatment for recurrent CDI (i.e., ≥1 prior recurrence — 2nd episode onward, NOT 3+). Approval based on PUNCH CD3 (Khanna Drugs 2022;82(15):1527-1538) — Phase 3 RCT, n=262, treatment success 70.6% Rebyota vs 57.5% placebo at 8 wk (Bayesian posterior probability of superiority 99.1%). Endorsed by ACG 2021 + AGA Living Guideline 2024 update. Traditional FMT remains investigational under FDA enforcement discretion; Rebyota is the regulatorily approved alternative.
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your C. difficile infection appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com